

## SUBJECT INDEX VOLUME 23

### A

A<sub>2</sub>-adrenoceptor supersensitivity, S2:S139  
 Abnormal neuroendocrine, S2:S97  
 Abstinent male alcoholics, S2:S156  
 Academia, S2:S10  
 Academically-striving countries, S2:S59  
 ACE gene, S2:S130  
 ACE I/D polymorphism, S2:S106  
 ACTH, 411  
 ACTH secretion, S2:S29  
 Activation, S4:S60  
 Activity, 444  
 Acute adolescent mania, S2:S124  
 Acute major depressive disorder, S2:S113  
 Acute schizophrenia, S2:S122  
 Addiction, S2:S17, S2:S103  
 Adenosine receptors, S4:S50  
 Administrative arrangements, S2:S9  
 Adolescent, S2:S82  
 Adrenal hyperplasia, S2:S60  
 Adrenal insufficiency, S2:S48  
 Adrenalectomy, 419  
 Adrenalectomy treatment, S2:S145  
 Adrenergic, 263, S4:S60  
 $\beta$ -Adrenergic receptors, 162  
 $\beta$ -,  $\alpha$ -Adrenergic receptors, S2:S3  
 Adrenoceptor up-regulation, S2:S138  
 $\alpha$ 2 Adrenoceptors, 697  
 Adverse early environment, S2:S5  
 Affective disorders, S2:S137  
 Aggression, 20, S2:S136, S2:S151  
 Agonists, S4:S32  
 $\kappa$  Agonists, S2:S145  
 AIDS, S2:S19, S2:S49–S51, S2:S113  
 Alcohol ingestion in the afternoon, S2:S117  
 Alcohol-exposed children, S2:S148  
 Alcoholics, abstinent male, S2:S156  
 Algorithm-based treatment, S2:S68  
 Allopregnanolone, S2:S24, S2:S40, S2:S72  
 Allotetrahydrodeoxycorticosterone, S2:S24  
 Alpha-2 adrenergic receptors, 240  
 Alpha-2 agonists, 263  
 Alzheimer's disease, S2:S8, S2:S48, S2:S52, S2:S94, S2:S128  
 Amiloride sensitive sodium channel, 188  
 AMPA, 335  
 AMPA receptors, 439, S2:S9  
 Ampakines, S2:S84  
 Amphetamine, 113, 654, S2:S17  
 Amphetamine receptor antagonists, S2:S118  
 Amygdala, 508, S2:S77  
 $\beta$ -Amyloid, S2:S52  
 Analgesia, 709  
 Analgesic responses, S2:S145  
 Androstadienone, S2:S28  
 Angiotensin I-converting enzyme, S2:S106  
 Animal models, 99, 223  
 Anorexia nervosa, S2:S104  
 Anticonvulsant drugs, S2:S3  
 Anticonvulsant theory, S2:S89  
 Antidepressant, 294  
 Antidepressant drugs, 285  
 Antidepressant effect, S2:S146  
 Antidepressant treatment, S2:S26, S2:S103

Antidepressant trials, S2:S44  
 Antidepressants, 89, 477, S2:S23, S2:S42–S44, S2:S74, S2:S95  
 Antioxidants, S2:S52, S2:S53  
 Antipsychotic, 56, 539  
 Antipsychotic drugs, 46, S2:S32, S2:S55, S2:S73  
 Antipsychotic therapy, S2:S32–S35, S2:S134  
 Antipsychotic treatment, S2:S144  
 Anti-saccade performance, S2:S151  
 Anxiety, S2:S61, S2:S65, S2:S77, S2:S86, S2:S133  
 Anxiety disorders, S2:S5, S2:S6, S2:S56, S2:S64, S2:S76, S2:S104  
 Anxiolytic metabolite, S2:S26  
 Anxiolytic-hypnotic drugs, S2:S24  
 Apomorphine, 99, 517  
 Approximate entropy, 560  
 Association study, 170  
 Astrocytes, S2:S131  
 Atenolol, S2:S138  
 Attention deficits, S2:S152  
 Atypical antipsychotic drugs, S2:S14  
 Atypical antipsychotics, 162  
 Atypical neuroleptics, S2:S55  
 Autoimmune disorders, S2:S30  
 Autonomic responses, S2:S119  
 Autoradiography, 285  
 AVP-neurophysin, S2:S50  
 Axis stress responses, S2:S2

### B

B12 vitamin, S2:S140  
 BDNF, 205  
 Beclomethasone-induced vasoconstriction (BIV), S2:S121  
 Bed nucleus of the stria terminalis, S2:S111  
 Behavior problems, S2:S100  
 Behavioral effects of NK<sub>1</sub>, S2:S23  
 Behavioral endocrine responses, S2:S119  
 Benign intracranial hypertension, S2:S136  
 Benzodiazapines, S2:S56  
 Benzodiazepine withdrawal syndrome, S2:S124  
 Benzothiophenes, S2:S79  
 Bilateral grand mal seizure, S2:S91  
 Biochemical markers, S2:S110  
 Biogenic amine systems, S2:S43  
 Bioinformatics, S4:S60  
 Biological Psychiatry, S2:S35  
 Biosynthesis, S2:S70  
 Bipolar adolescents, S2:S124  
 Bipolar affective disorder, 1  
 Bipolar disorder, S2:S3, S2:S12, S2:S64, S2:S68, S2:S75, S2:S87, S2:S107, S2:S132  
 Blood glucose metabolism, S2:S123  
 Body, S2:S8  
 Body mass index, 13  
 Body-mind interplay, S2:S40  
 Bone mineral density, S2:S34  
 Brain, 428, S2:S92–S94  
 Brain aging, S2:S94  
 Brain closure function, S2:S152

Brain damage, S2:S86  
 Brain development, S2:S12, S2:S70  
 Brain fear circuits, S2:S65  
 Brain functions, S2:S140  
 Brain plasticity, S2:S36  
 Brain redox systems, S2:S52–S54  
 Brain regional structures, S2:S64  
 Brazilian study, S2:S114  
 Brownian dynamics, S4:S60  
 BTCP, 316  
 Bulimia nervosa, S2:S104  
 Buprenorphine, 326  
 Business ethics, S2:S16

### C

C-6 glioma cells, S2:S131  
 Caesarean section, 654  
 Calcium, 690  
 Calcium-calmodulin kinase type II, S2:S18  
 cAMP, S2:S3  
 cAMP-dependent protein kinase, 216  
 Carbamazepine, S2:S3  
 Carbohydrate tolerance, S2:S80  
 Carbon monoxide, S2:S30  
 Carfentanil, 326  
 Cataplexy, 34, 528  
 CBF, 388  
 CCK, 205  
 CCK-4 induced panic, S2:S157  
 Cell biology, S2:S35  
 Cell communication, S2:S15  
 Cell-mediated immunity, 89  
 Central nervous system, S2:S12, S2:S92  
 Cephalalgia, S2:S132  
 Cerebral blood flow, 263  
 Cerebral function, S2:S67  
 Cerebralum®, S2:S127  
 Cerebrovascular disease, S2:S127  
 CGS 8216, 179  
 Chang, S2:S22  
 Channel blockers, S2:S75  
 Channel openers, S2:S75  
 Chaos, 560  
 Chemosensory transduction, S2:S27  
 Child, S2:S82  
 Childhood depression, 591  
 Cholesterol, S2:S24  
 CHR, S2:S49  
 Chromaffin cells, 709  
 Chromatin conformation, 1  
 Chromogranins, 46  
 Chromosome 18, 1  
 Chronic depression, S2:S113  
 Chronic fatigue syndrome (CFS), S2:S76, S2:S114  
 Cigarette smoking, S2:S150  
 Cigarettes, 351  
 Cingulate cortex, 633  
 Cirazoline, 697  
 Circadian salivary cortisol levels, S2:S105  
 Circannual melatonin, S2:S108  
 Circuitry pharmacotherapy, S2:S73–S75  
 Clinical diagnosis, S2:S115

Clinical Global Impression Scale, S2:S116  
 Clinical trial, 365  
 Clinical trials, S2:S43  
 Clobazam, S2:S3  
 Clonidine, 138, 697  
 Clonidine administration, S2:S132, S2:S139  
 Clorniphen, S2:S78  
 Clozapine, 151, 162, S2:S54, S2:S116, S2:S123, S2:S135  
 CNS, 428  
 Cocaine, 316, 335, 444, 455, 560, 577, S2:S17, S2:S46, S2:S133  
 Cocaine self-administration, 138  
 Cognition, 113, 240, S2:S51, S2:S79, S2:S92–S94  
 Cognitive aging, S2:S94  
 Cognitive dysfunction, S2:S128  
 Cognitive functioning, S2:S8  
 Cognitive therapeutic considerations, S2:S99  
 Collaboration, S2:S58  
 Collegium International  
 NeuroPsychopharmacologicum, S2:S9  
 Comorbid psychiatric disorders of somatic illness, S2:S143  
 Complex, S4:S5  
 Conditioned fear stress, 276  
 Conditioning, 455  
 Consultation-liaison psychiatry, S2:S100  
 Convulsive therapy, S2:S91  
 Correlated mutation analysis, S4:S60  
 Cortex, 455  
 Corticosteroid receptors, 477  
 Corticosterone, 419  
 Corticotropin releasing factor, S2:S1, S2:S4, S2:S29, S2:S60, S2:S77, S2:S149  
 Corticotropin-releasing hormone, 577, S2:S81  
 Corticotropin-releasing hormone system, S2:S124  
 Cortisol, 411, 502, S2:S47  
 CRF, S2:S6  
 CRF cells, S2:S111  
 CRF neurocircuits, S2:S63  
 CRF receptor antagonists, S2:S5  
 CRF<sub>1</sub>-selective antagonist, S2:S119  
 CRH, 477  
 CRH hypothesis, S2:S6  
 CRH system, S2:S76  
 CRH type-1 receptor antagonism, S2:S119  
 CSF, 455  
 Cultural formulation, S2:S37  
 Cultural framework, S2:S95  
 Cultural specificity, S2:S45  
 Culture, S2:S37  
 Cyclic AMP, 198  
 Cyclic Amp response element binding protein, S2:S18  
 Cytokines, 89, S2:S60

## D

D4 receptors, 405  
 D-allele, S2:S106  
 Daylength variation rate, S2:S108  
 Dehydroepiandrosterone, S2:S25, S2:S56  
 Delayed alternation, 547  
 Delayed-type hypersensitivity, S2:S105  
 Dementia, S2:S126, S2:S136  
 Depressed men, S2:S147  
 Depression, 89, 205, 250, 411, 477, S2:S26, S2:S34, S2:S35, S2:S47, S2:S57, S2:S59–S61, S2:S62, S2:S65, S2:S76, S2:S80–S83, S2:S89, S2:S101, S2:S103, S2:S104, S2:S121, S2:S133, S2:S138, S2:S144, S2:S153  
 Depression ideation, S2:S139  
 Depression subtypes, S2:S113

Depressive disorders, S2:S44, S2:S64, S2:S95, S2:S105, S2:S113, S2:S115  
 Depressive patients, S2:S130  
 Development, 444, 502  
 Dexamethasone suppression test (DST), S2:S110  
 Dexamethasone treatment, S2:S145  
 Deydroepiandrosterone, S2:S40  
 D-Fenfluramine challenge test, S2:S89, S2:S122  
 DHEA, 69, S2:S46–S48, S2:S127  
 DHEAS, 276  
 DHEA-S, S2:S25, S2:S127  
 Diabetes, S2:S106, S2:S123  
 Dialysis, 335  
 Diazepam, 179  
 Diencephalic stimulation theory, S2:S90  
 Differential gender effects, S2:S32  
 Dimerization, S4:S32, S4:S41, S4:S60  
 Dimers, S4:S5  
 Discomfort index, S2:S109  
 Disulfide-crosslinking, S4:S19  
 Diurnal cortisol, S2:S19  
 DNA methylation, 1  
 DNA technology, S2:S8  
 Dog, 34  
 DOI, 569  
 Domain swapping, S4:S60  
 Domains, S4:S60  
 Dopamine, 79, 205, 250, 316, 365, 375, 405, 455, 654, 667, S2:S17, S2:S35, S2:S53, S2:S93, S2:S118  
 Dopamine D3 receptor gene, 1  
 Dopamine hormones, S2:S148  
 Dopamine neurotransmission, S2:S137  
 Dopamine receptor antagonists, S2:S118  
 Dopamine receptor D2, S2:S137  
 Dopamine receptor D3, S2:S137  
 Dopamine receptors, 307, 595, S4:S32, S4:S50  
 Dopaminergic system, 528  
 Dorsal raphe, 294  
 Double-blind, 591  
 Doxorubicin, S2:S118  
 Drug abuse, 113, 307, 633  
 Drug dependence, 127  
 Drug development, S2:S13  
 Drug metabolism, S2:S32  
 Drug tissue distribution, 428  
 Drug-free, 13  
 Drugs of abuse, S2:S19  
 Dysthymic patients, S2:S113

## E

Early-onset schizophrenia, S2:S126  
 Eating disorders, S2:S25, S2:S96, S2:S104  
 Ecstasy, 388, 396  
 ECT, 439  
 Educational programs, S2:S59  
 EEDQ, 595  
 EEG complexity changes, S2:S125  
 EEG sleep, S2:S82  
 Efficacy, S2:S42, S2:S43  
 Elderly men, S2:S136  
 Elderly patients, S2:S126  
 Electroconvulsive therapy (ECT), S2:S69, S2:S89–S91, S2:S127  
 Electroconvulsive treatments, S2:S62  
 Electrophysiology, 419  
 ELISPOT technique, S2:S110  
 Emission computed tomography, 667  
 Emotional functioning, S2:S8  
 Emotional stressor, S2:S111  
 $\beta$ -END, S2:S117  
 Endocrine dysfunction, S2:S34  
 Endocrine functions, S2:S80–S83  
 Endocrine system, S2:S59

Endogenous pharmacology, S2:S128  
 Environmental factors, S2:S109  
 Epigenetics, 1  
 Epilepsy, 263  
 Epimutation, 1  
 Episodic psychiatric disorders, S2:S3  
 Estradiol, 69, S2:S56, S2:S92  
 Estrogen, S2:S41, S2:S66, S2:S92–S94, S2:S107  
 Estrogen receptor  $\beta$ , S2:S92  
 Estrogen replacement therapy, S2:S94  
 Estrogen supplementation, S2:S153  
 Estrogen therapy, S2:S126  
 Estrogen-serotonin link, S2:S98  
 Ethanol, S2:S72  
 Ethics, S2:S16  
 Euphoria, 455  
 Euthyroid psychiatric subjects, S2:S142  
 Evolution, S2:S12  
 Evolutionary trace analysis, S4:S60  
 Experimental psychopathology, S2:S35

## F

Federal Drug Administration, S2:S44  
 Female depression, S2:S130  
 Female rat brain, S2:S109  
 Female rats, S2:S112  
 Female Sprague-Dawley rats, S2:S109  
 FG7142K, 405  
 Fibromyalgia, S2:S76  
 First episode schizophrenia, S2:S110  
 Fluorine MTS, 428  
 Fluoxetine, 250, 428, 591, S2:S26, S2:S130  
 Fluvoxamine, 428  
 Food intake, 455  
 Forced migrants, S2:S143  
 Fos, 162  
 Fos-related antigens, 307  
 France, S2:S15, S2:S21  
 Free radicals, S2:S52  
 Frontal, 455  
 Frontoparietal cortex, 179  
 Functional brain imaging, S2:S77  
 Functional imagery, S2:S15, S2:S54  
 Functional rescue, S4:S60

## G

G protein, S4:S5, S4:S60  
 G protein-coupled receptors, S4:S19, S4:S32, S4:S50, S4:S60  
 GABA agonist, 633  
 GABA mediated inhibition, S2:S26  
 GABA<sub>A</sub> receptor, S2:S72  
 GABA(B) receptor, S4:S41  
 GABA<sub>A</sub> receptors gene expression, S2:S24  
 GABRA5 gene locus, S2:S136  
 Gaddum, S2:S22  
 Galanin receptors, 127  
 Gamma-aminobutyric acid, S4:S41  
 Gender, S2:S32–S35, S2:S123  
 Gender differences in brain stems, S2:S64–S66  
 Gender specific, S2:S28  
 Gene expression, 46, S2:S15, S2:S70  
 General medicine, S2:S102  
 General practitioners, S2:S98–S99, S2:S102  
 Gene-related peptide, S2:S118  
 Genetic association, 1  
 Genetic association study, S2:S136  
 Genetic enhancement, S2:S18  
 Genetic linkage, 1  
 Genetic models, 223  
 Genetic risk, S2:S12  
 Genetics, S2:S7  
 Genital herpes, S2:S31

Genomic imprinting, 1  
 Geomagnetic factors, S2:S109  
 Geomagnetic field, S2:S108  
 Geomagnetic index DST, S2:S109  
 Germany, S2:S16  
 GH<sub>3</sub> cells, 676  
 Globalization, S2:S9, S2:S20  
 Glucocorticoid antagonists, S2:S56  
 Glucocorticoid feedback, 411  
 Glucocorticoid negative feedback, S2:S65  
 Glucocorticoid receptor, S2:S131  
 Glucocorticoid receptors antagonists, S2:S59–S61  
 Glucocorticoids, S2:S49, S2:S101  
 Glucose tolerance, S2:S123  
 Glutamate, 223, 335, S2:S93  
 Glutamate mechanisms, S2:S83–S87  
 Glutamate synapse, S2:S53  
 Glycemic peak delay, S2:S123  
 Gonadal hormones, S2:S109, S2:S114  
 Gonadal steroids, S2:S96, S2:S109  
 Gonadectomy, S2:S114  
 Gonadotropins, S2:S28  
 Government, S2:S43  
 Governmental agencies, S2:S10  
 GPCR, S4:S60  
 Grand mal seizure, S2:S91  
 Growth hormone, S2:S82  
 Growth hormone-releasing hormone, S2:S80, S2:S81, S2:S82  
 GSK-3B, S2:S38  
 Guanfacine, 240  
 Guinea pig, 654  
 Gynecology and psychiatry, interface between, S2:S96–S98

## H

Hallucinogens, 569  
 Haloperidol, 151, 517, S2:S54, S2:S89, S2:S150  
 Haloperidol treatment, S2:S123  
 Head shakes, 569  
 Health care, S2:S7  
 Health care aspects, S2:S15–S16  
 Health care policy, S2:S7  
 Healthy smokers, S2:S134  
 Heart rate, 560  
 Help-seeking Pathways, S2:S95  
 Heroin, 113  
 Heterodimerization, S4:S50  
 Heterodimers, S4:S5  
 Heterosexuals, S2:S120  
 High melatonin excretors, S2:S107, S2:S138  
 High risk subjects, S2:S117  
 High-resolution imaging, S2:S126  
 Hippocampal CA1 pyramidal cells, S2:S92  
 Hippocampal circuitry, S2:S92  
 Hippocampus, 294, 419, 439, 697, S2:S17, S2:S38, S2:S90  
 Hippocrates, S2:S100  
 HIV, S2:S18, S2:S19  
 HIV-1 infection, S2:S51, S2:S133  
 H<sub>2</sub>O-PET, 388  
 Hormonal interventions, S2:S14  
 Hormonal replacement therapy, S2:S14, S2:S45, S2:S66  
 Hormones, S2:S18–S20, S2:S56–S57  
 HPA, 477  
 HPA axis, 411, S2:S111, S2:S117  
 HPA system, S2:S32, S2:S130  
 5-HT, 601  
 5-HT<sub>1A</sub>, 20  
 5-HT<sub>2A</sub> receptor, 69, 569  
 5-HT<sub>3</sub> receptor, S2:S71  
 5-HT receptor sub-types, S2:S115  
 5-HT receptors, 89  
 5-HT-1A receptor, S2:S91

Human, 388  
 Human brain, 351  
 Human 5-HT<sub>1A</sub> receptor, 285  
 Human sexuality, S2:S94–S95  
 Hydrocortisone treatment, S2:S124  
 Hypercortisolism, S2:S60  
 Hyperforin, 188, S2:S88  
 Hypericum perforatum, S2:S88  
 Hyperprolactinemia, S2:S33  
 Hypogonadal men, S2:S147  
 Hypothalamic-pituitary-adrenal (HPA) axis, S2:S2, S2:S6, S2:S14, S2:S29, S2:S30, S2:S35, S2:S50, S2:S60, S2:S65, S2:S76, S2:S88, S2:S146  
 Hypothalamic-pituitary-gonadal (HPG) axis, S2:S66  
 Hypothalamic-pituitary-thyroid (HPT) axis, S2:S67, S2:S69  
 Hypothalamo-pituitary-adrenal (HPA) system, S2:S80  
 Hypothalamus, S2:S57, S2:S91  
 Hypothermia, 20  
 Hypothyroidism, S2:S106

## I

I/D polymorphisms, S2:S130  
 Idiographic formulation, S2:S95  
 IGF-1, S2:S118  
 Imidazoline receptors, 697  
 Immediate early gene, 439  
 Immediate-early genes, 162  
 Immobility, 375  
 Immune function, S2:S19  
 Immune system, S2:S18–S20, S2:S101  
 Immunity, S2:S31  
 Impaired glucose tolerance, S2:S123  
 Impulsivity, S2:S134  
 In situ hybridization, 127  
*In vivo* electrophysiology, 294  
 Ingestive behavior, 455  
 Inositol 1,4,5-trisphosphate, 179  
 Insomnia, S2:S104  
 Insurance, S2:S16  
 Interferon- $\alpha$ , S2:S133  
 Intervention, S2:S99  
 Intracellular messengers, S2:S3  
 Intracellular recording, 419  
 Intrathecal, 709  
 Intravenous drug use (IDU), S2:S113  
 Intravenous infusion of sodium lactate, S2:S135  
 Inwardly rectifying K<sup>+</sup> current, 676  
 IQNB, 56  
 Ischemic brain damage, S2:S86

## K

Ketamine, 645, S2:S86  
 Ketanserin, 396  
 Kraepelin, S2:S123, S2:S140

## L

Lamotrigine, S2:S3  
 Late-life major depression, 587  
 Latency, S2:S146  
 Latent inhibition, 151  
 Laterality, 502  
 LC/NE system, S2:S76  
 Lead, 444  
 Learning, S2:S18  
 Learning disabilities, S2:S106  
 Learning/memory performance, S2:S114  
 Leeman, S2:S22

Legislation, S2:S21  
 Leptin, 13  
 Levothyroxine, S2:S68  
 Lithium, S2:S39, S2:S57, S2:S62, S2:S69  
 Lithium prophylaxis, S2:S87  
 Lithium response, S2:S124  
 Lithium treatment, S2:S156  
 Locomotion, 633, 654  
 Locomotor activity, 547  
 Locus coeruleus, 127  
 Lofexidine, 138  
 Long-term depression, S2:S17  
 Long-term potentiation (LTP), S2:S17, S2:S125  
 Lordosis quotient, S2:S112  
 Low melatonin depressives, S2:S140  
 Low melatonin excretors, S2:S107, S2:S138  
 Low risk subjects, S2:S117  
 Low serum triiodothyronine, S2:S142  
 LY354740, 569  
 Lymphocytes, S2:S110

## M

Maghrebian psychiatry, S2:S21  
 Magnetic resonance spectroscopy, 428, S2:S90, S2:S126  
 Major depression, 294, 601  
 Major depressive disorder, S2:S44, S2:S64, S2:S105, S2:S113, S2:S115  
 Major psychiatric disorders, S2:S136  
 Male depression, S2:S130  
 Male dysthymia, S2:S147  
 Management of depression, S2:S103  
 Manic depression, S2:S39, S2:S106  
 Maprotiline, S2:S130  
 Maternal care, S2:S13  
 Maternal deprivation, 99  
 Mazindol, 365  
 MDD, 591  
 MDMA, 388, 396  
 Medical ethics, S2:S16  
 Mediterranean, S2:S20–S21, S2:S45  
 Medullary neurons, S2:S111  
 Melatonin, S2:S107, S2:S108, S2:S139, S2:S140, S2:S154  
 Memory, 198, 405, S2:S18, S2:S140  
 Memory training, S2:S106  
 Menopause, S2:S45, S2:S98, S2:S153  
 Menstrual cycle, S2:S40, S2:S155  
 Menstrual dysfunction, S2:S33  
 Menstrually-related disorders, S2:S26  
 Mental and neurological illnesses, S2:S104  
 Mental disorders, S2:S24–S27, S2:S102  
 Mental health, S2:S98  
 Mental health advocacy, S2:S11  
 Mental health programs, S2:S9  
 Mental health responsibility, S2:S98  
 Mental health services, S2:S999, S2:S102  
 Mesolimbic dopamine system, S2:S17  
 Metabolic functioning, S2:S15  
 Metabolic syndrome, S2:S76  
 Metabotropic glutamate receptor agonists, S2:S84, S2:S86  
 Metabotropic glutamate receptors, S2:S86  
 Metastatic breast cancer, S2:S19  
 Methamphetamine, S2:S52  
 Methysergide, S2:S145  
 mGlu2/3 receptors, 569  
 Microdialysis, 138  
 Middle East, S2:S20–S21, S2:S46, S2:S58  
 Mind, S2:S8, S2:S79  
 MK-801, 198, 547  
 Mnestic block syndrome, S2:S129  
 Modern psychology, S2:S100  
 Molecular dynamics, S4:S60  
 Molecular genetics, S2:S8

Molecular modelling, S4:S60  
 Monoamine neurotransmitters, S2:S66  
 Monoamine transmitters, S2:S53  
 Monotherapy, S2:S134  
 Mood, S2:S77, S2:S82  
 Mood disorder, 690  
 Mood disorders, S2:S5, S2:S6, S2:S67, S2:S68, S2:S88, S2:S116  
 Mood disorders in women, S2:S44–S45  
 Mood enhancing properties, S2:S47  
 Mood modulators, S2:S66–S69  
 Mood stabilizers, S2:S38–S39, S2:S75  
 Mood symptoms, S2:S66  
 Morocco, S2:S37  
 Morphine, 307, 455, S2:S113  
 Morphine orlorazepam withdrawal, S2:S149  
 Mouse, 127  
 Mouse cerebral hemispheres, S2:S131  
 Moxonidine, 697  
 Mu opioid receptors, 326  
 Multidisciplinary, S2:S35–S37  
 Multinational study, S2:S154  
 Multiple chemical sensitivity syndrome (MCS), S2:S114  
 Multiple receptor targets, S2:S73  
 Multiple synapses, S2:S14  
 Multisystems, S2:S73–S75  
 Muscarinic acetylcholine receptors, S4:S19  
 Muscarinic receptor, 56  
 Myristoylated alanine-rich C kinase substrate, S2:S38

## N

Na<sup>+</sup>-H<sup>+</sup> exchange, 188  
 N-acetyl aspartyl glutamate, S2:S85  
 Naloxone, 79  
 Narcolepsy, 34, 528  
 Nasal pathway to the brain, S2:S27–S28  
 National Alliance for the Mentally Ill, S2:S11  
 National Institute of Mental Health, S2:S67  
 N-[1-(2-benzo[b]thiophenyl)-cyclohexyl]piperidine, 316  
 Negative symptom, 162, 365, 375  
 Neocortex, S2:S18  
 Nepal, S2:S148  
 Neural transplants, 709  
 Neuroactive steroids, S2:S26, S2:S70–S73  
 Neurocognitive functioning, S2:S150  
 NeuroCybernetic Prosthesis System, S2:S144  
 Neurodegenerative diseases, S2:S127  
 Neurodevelopment, 223  
 Neuroendocrine challenge, S2:S115  
 Neuroendocrine observations, S2:S119  
 Neuroendocrine responses, S2:S51, S2:S149  
 Neuroendocrine system, S2:S91  
 Neuroendocrine tests, S2:S87–S89  
 Neurogenesis, S2:S38  
 Neuroimaging, S2:S64  
 Neuroleptics, S2:S107  
 Neuromodulators, S2:S74  
 Neuronal changes, S2:S8  
 Neuropathogenesis, S2:S133  
 Neuropeptide Y (NPY), S2:S61, S2:S81, S2:S118  
 Neuropeptides, 46, S2:S61–S63  
 Neurophysiological evaluation, S2:S132  
 Neuroplasticity, S2:S38  
 Neuroprotection, 205, S2:S70  
 Neuroprotective activity, S2:S118  
 Neuroprotective effects, S2:S39  
 Neuropsychiatry, S2:S9–S11  
 Neuropsychological pattern, S2:S120  
 Neuroreceptor PET/SPECT imaging, S2:S155  
 Neuroregulatory effects, S2:S96  
 Neurosteroidogenic enzymes, S2:S70

Neurosteroids, 276, S2:S14, S2:S24–S27, S2:S39, S2:S40  
 Neutensin (NT), S2:S62, S2:S118  
 Neurotransmitters, S2:S74  
 Neurotrophic actions, S2:S78  
 Neurotrophic factors, S2:S62  
 Nicotine, 79, 351, S2:S134  
 Nicotine nasal spray, S2:S150  
 Nicotinic receptors, 351  
 Nitric oxide, S2:S30  
 NMDA, 645  
 NMDA receptors, 198, 539, S2:S85  
 Nociception, 709  
 Nocturnal thyroid-stimulating-hormone, S2:S80  
 Noncognitive psychiatric symptoms, S2:S126  
 Nongovernmental agencies, S2:S10  
 Noradrenaline, 162, S2:S62  
 Norepinephrine, 240, 250, S2:S69, S2:S74  
 Norepinephrine system, S2:S1–S3  
 Norepinephrine antidepressants, S2:S130  
 Normal ovarian endocrine, S2:S97  
 North Africa, S2:S21  
 Nortriptyline, 587  
 Novel antidepressant interventions, S2:S20  
 Novel antipsychotic, S2:S155  
 NPY, 205  
 Nucleus accumbens, 307, 335

## O

Obsessive compulsive disorder, S2:S36, S2:S98, S2:S132  
 Occupancy, 595  
 Octreotide, S2:S136  
 Olanzapine, 56, 162, 250, S2:S150  
 Oligomerization, S4:S5, S4:S32  
 Operational arrangements, S2:S9  
 Opiate dependence, 326  
 Opiate withdrawal, 307  
 Opiates, 79, 326, 455  
 Opioid peptides, 709  
 Opioids, S4:S5  
 Oral contraceptives, S2:S24, S2:S24  
 Osteoporosis, S2:S34  
 Outcome indicator, S2:S142  
 Ovarian function, S2:S33  
 Ovariectomy, 69, S2:S114  
 Oxidative stress, S2:S54

## P

Panic anxiety, S2:S135  
 Panic disorder, S2:S24, S2:S157  
 Parameters, S2:S20  
 Parasympathetic, 560  
 Parent-of-origin effect, 1  
 Paroxetine, 587, S2:S133  
 PAT brain mitochondria, S2:S131  
 Patient needs, S2:S100  
 Patient sampling, S2:S42  
 Pavlov, I.P., S2:S152  
 Pavlovian conditioning, 633  
 P-chlorophenylalanine, S2:S114  
 Pentraxin, 439  
 Peptides, S2:S81  
 Perimenopause, S2:S98  
 Perinatal hypoxia, 654  
 Peripheral nervous system, S2:S70  
 PET, 263, 508  
 Pharmacokinetic observations, S2:S119  
 Pharmacokinetics, 428  
 Pharmacological therapies, S2:S104, S2:S153

Phencyclidine, 375, 517, S2:S83, S2:S86  
 Phenethylamines, 569  
 Phenomenology, S2:S123  
 Pheromones, S2:S27–S28  
 Phosphatidylinositol, S2:S3  
 Phosphodiesterase, 198  
 Physical disorders, S2:S155  
 Physical stressors, S2:S111  
 Pindolol, 285  
 Placebo, 591  
 Plasma cortisol levels, S2:S105  
 Plasma neurosteroid, S2:S24  
 Plasma prolactin, S2:S150  
 Platelet, 216, 690  
 Polymorphism, 170, S2:S154  
 Positron emission tomography, 285, 326  
 Postmortem, 351  
 Postpartum cycloid, S2:S97  
 Postpartum depression, S2:S116, S2:S121  
 Postpartum psychoses, S2:S97  
 Posttraumatic stress disorder (PTSD), S2:S76, S2:S105, S2:S120, S2:S121  
 Potassium currents, S2:S75  
 Prediction, 591, S2:S87  
 Prefrontal cortex, 79, 113, 162, 375, 405, S2:S84  
 Pregnenolone, S2:S39  
 Pregnenolone, S2:S39  
 Premenstrual dysphoric disorder (PMDD), S2:S45, S2:S96, S2:S97, S2:S122, S2:S154  
 Premenstrual syndrome (PMS), S2:S4, S2:S45, S2:S97, S2:S112, S2:S156  
 Prepulse inhibition, 99, 517, 547, 623, 654  
 Primary care, S2:S98, S2:S99, S2:S100, S2:S102  
 PRIME-MD modules, S2:S101  
 Problem-oriented practical review, S2:S100–S104  
 Processing deficits, S2:S128  
 Progesterone, S2:S41, S2:S96, S2:S116  
 Progesterone metabolites, S2:S40  
 Progesterone therapy, S2:S156  
 Progestins, S2:S66  
 Progestogens, S2:S41  
 Prolactin release, S2:S90  
 Prolactin response, S2:S144  
 Prolactinemia, S2:S110  
 Prolactin-sparing antipsychotic drugs, S2:S33  
 Protein regulation, 539  
 Prozac, S2:S142  
 Psoriasis, S2:S76  
 Psychiatric care, S2:S95  
 Psychiatric diagnosis, S2:S95  
 Psychiatric disorders, S2:S71, S2:S140  
 Psychiatry, S2:S99, S2:S100  
 Psychiatry and gynecology, interface between, S2:S96–S98  
 Psychobiological reactions, S2:S144  
 Psychological disorders, S2:S155  
 Psychological effects, 388  
 Psychological evaluation, S2:S132  
 Psychoneuroendocrinology of stress, S2:S29–S32  
 Psychopathology, S2:S36, S2:S148  
 Psychopharmacological approaches, S2:S104  
 Psychoses, S2:S116  
 Psychosexual development, S2:S142  
 Psychosocial maturity, S2:S100  
 Psychotherapeutic, S2:S99  
 Psychotic depression, S2:S6  
 Psychotic features, S2:S120  
 Psychotic major depression, S2:S56  
 Psychotropic drug action, S2:S54  
 Psychotropic drug use, S2:S75  
 Psychotropic medications, new, S2:S12–S13  
 Public health care, S2:S15

**Q**

QA/QC parameters, S2:S46  
 Quality assurance, S2:S7, S2:S45–S46

**R**

R121919, S2:S119, S2:S149  
 Raclopride, 595  
 Raloxifene, 69, S2:S78  
 Rat, 20, 151, 179, 577, 633  
 Rat brain, S2:S118  
 Rat hippocampus, S2:S125  
 Rat strains, 99  
 rCBF, 508  
 Rearing behavior, S2:S63  
 Reboxetine, S2:S1, S2:S2  
 Receptor autoradiography, 127  
 Receptor binding, 351  
 Receptor dimers, S4:S19  
 Receptor oligomerization, S4:S19  
 Receptor–receptor interactions, S4:S50  
 Recognition, 508  
 Recovery sleep, S2:S82  
 Refugees, S2:S143  
 Rehabilitation, S2:S143  
 Reinforcement, 577  
 Relapse, 138  
 Religion, S2:S99  
 Religious practice, S2:S37  
 REM sleep, 34, 528  
 Repetitive transcranial magnetic stimulation, S2:S20  
 Reproductive events, S2:S40  
 Reproductive hormones, S2:S65  
 Reproductive-related disorders, S2:S14  
 Research agenda, S2:S58  
 Resident-intruder, 20  
 Respiratory sinus arrhythmia, 560  
 Reuptake inhibitor, 294, 316  
 Rhesus macaques, 502, S2:S113  
 Rhett's Syndrome, S2:S8  
 Risk factor, S2:S121  
 Risperidone, 676, S2:S33, S2:S120  
 Ritanserin, 151  
 Rolipram, 198  
 rTMS, 205  
 Russia, S2:S143  
 Russian hospitals, S2:S142

**S**

Salivary cortisol levels, S2:S153  
 Schizophrenia, 1, 56, 99, 162, 170, 216, 223, 351, 365, 517, 539, 547, 623, 645, 654, 667, S2:S12, S2:S32–S35, S2:S54, S2:S55, S2:S62, S2:S83, S2:S85, S2:S86, S2:S89, S2:S92, S2:S122, S2:S123, S2:S135, S2:S150  
 Schizophrenic patients, S2:S107, S2:S144, S2:S150  
 Schizotypy, S2:S152  
 Schwann cells, S2:S70  
 Scrizotypy, S2:S151  
 Seasonal bimodal pattern, S2:S108  
 Seasonal pattern of melatonin secretion, S2:S108  
 Secularization, S2:S21  
 Seizure, S2:S90  
 Selective estrogen receptor modulators (SERMs), S2:S112  
 Selective NRI, S2:S2  
 Selective serotonin reuptake inhibitors (SSRIs), S2:S1, S2:S42, S2:S45, S2:S56, S2:S66  
 Self-administration, 316, 577  
 Self-hypnosis, S2:S31  
 Self-reported sleep disorders, S2:S109  
 Sensitization, 335, 444  
 Sensorimotor, 517  
 Sensorimotor regulation, 623  
 Serotonergic antidepressants, S2:S130  
 Serotonergic system, S2:S50  
 Serotonergic transmission, S2:S91  
 Serotonin, 20, 89, 250, 375, 388, 396, 419, 569, 601, 623, 690, S2:S29, S2:S62, S2:S69, S2:S73, S2:S74, S2:S84, S2:S96  
 Serotonin (5-HT), S2:S110  
 Serotonin 2A receptor, S2:S92  
 Serotonin 2A receptor gene, 1  
 Serotonin deficiency, S2:S112  
 Serotonin 5-HT1A receptors, 547  
 Serotonin receptors, S2:S109, S4:S32  
 Serotonin reuptake inhibitor, 13, S2:S122  
 Serotonin transporter promoter (5-HTTLPR), 587  
 Serum levels, S2:S140  
 Sex difference, S2:S44  
 Sex steroid-related aggression, S2:S122  
 Sex steroid-related genes, S2:S154  
 Sex steroids, S2:S96  
 Sexology, S2:S122  
 Sex-specific events, S2:S44  
 Sexual disorders, S2:S95, S2:S122  
 Sexuality, S2:S94  
 Sigma receptor, 539  
 Sigma<sub>1</sub> receptors, 276  
 Signal transduction, S2:S15, S4:S5, S4:S41  
 Single receptor targets, S2:S73  
 Site-directed mutagenesis, S4:S19  
 Skin conductance, 508  
 Sleep, 34, S2:S80–S83, S2:S146  
 Sleep deprivation, S2:S80, S2:S82, S2:S146  
 Sleeping disorders, S2:S104  
 Slow wave sleep, S2:S81  
 Smoking, 351  
 Smooth pursuit eye movements, 645  
 Social isolation, S2:S148  
 Social-Stress Disorders (SSD), S2:S143  
 Sodium valproate, S2:S3, S2:S135  
 Soluble TNF receptors, 13  
 Somatic diagnoses, S2:S101  
 Somatic intersexuality, S2:S142  
 Somatic symptoms, S2:S101  
 Somatophorm disorders, S2:S142  
 Somatostatin, S2:S81  
 Somatostatin receptor, 179  
 Specific behavioral actions, S2:S42  
 Specific estrogen receptors modulators, S2:S78–S79  
 SPECT, 56  
 SPECT imaging, 240  
 Spiritual psychiatry, S2:S35  
 Spirituality, S2:S99, S2:S100  
 Spirituality and mental health, S2:S99–S100  
 SSRIs, S2:S112, S2:S153  
 St. John's Wort, 188, S2:S88  
 Startle, 517, 623  
 Startle reflex, 547  
 Steroid hormone action, S2:S71  
 Steroids, S2:S39–S42  
 Stimulant, 113  
 Stimulant abuse medications, S2:S155  
 Strain differences, 623  
 Stress, 138, 405, 411, 477, S2:S18, S2:S29–S32, S2:S50, S2:S53, S2:S59, S2:S60, S2:S61, S2:S77, S2:S101  
 Stress control, S2:S29  
 Stress hormone systems, S2:S6, S2:S80  
 Stress hormones, S2:S129, S2:S148  
 Stress reduction, S2:S4  
 Stress responses, S2:S13, S2:S76  
 Stress sensitization, S2:S32  
 Stress-induced disorders, S2:S76–S77

Stress-related hormones, S2:S53  
 Subjective, 455  
 Substance abuse, S2:S103  
 Substance P, S2:S22–S23, S2:S29, S2:S110  
 Substance P antagonists, S2:S22–S23  
 Subtype, S4:S5  
 Subtype synapse, S2:S14  
 Suicidal ideation, S2:S139  
 Sulpiride, 528  
 Superoxide dismutase, 170  
 Survival, S2:S19  
 Sympathetic, 560  
 Synapse-targeted psychopharmacology, S2:S54–S56  
 Synaptic plasticity, S2:S17–S18, S2:S53  
 Synaptic spines, S2:S53  
 Synaptic vesicles, 667  
 Synaptogenesis, S2:S38  
 Synaptosomal uptake inhibition, 188  
 Synergy, S4:S5

**T**

Tamoxifen, 69  
 Tamoxiphen, S2:S78  
 Tardive dyskinesia, 170  
 Target genes, S2:S70  
 TBE glucocorticoid receptor, S2:S131  
 Testosterone, 502, S2:S28, S2:S56  
 Testosterone levels, S2:S136, S2:S147  
 Testosterone replacement, S2:S147  
 Tetrabenazine, 667  
 3 $\alpha$ , 5 $\alpha$ -Tetrahydroprogesterone, S2:S25  
 Therapeutic potential, S2:S22  
 Thyrotropin, S2:S156  
 Thyroid disturbances, S2:S105  
 Thyroid function, S2:S67, S2:S115  
 Thyroid hormone receptors, S2:S69  
 Thyroid hormones, S2:S57, S2:S66–S69  
 Thyrotropin-releasing hormone (TRH), 34, S2:S57  
 Thyroxine, S2:S66  
 T-maze, S2:S36  
 Tobaloperidol, S2:S122  
 Topiramate, S2:S3  
 Total sleep deprivation, S2:S82  
 Transcranial magnetic stimulation, S2:S146  
 Transcription factors, S2:S52  
 Transcultural Psychiatry, S2:S35  
 Transsexual patients, S2:S120  
 Treatment, S2:S84  
 Treatment response, 690  
 Tricyclic antidepressants, 13, S2:S2, S2:S42, S2:S56  
 Triiodothyronine, S2:S57, S2:S66, S2:S68  
 Triphenylethylenes, S2:S79  
 Trophic actions, S2:S70  
 Trophynotropine "Adement," S128  
 Trophynotropine group, S2:S127  
 Tryptophan depletion, S2:S115  
 Tryptophan-free drink, 601

**U**

UNICEF, S2:S9  
 Unipolar major depression, S2:S68

**V**

Vagal tone, 560  
 Vagus nerve stimulation, S2:S144  
 Val108Met, S2:S151  
 Valproate augmentation, S2:S134  
 Vasoactive IC drugs, S2:S122  
 Vasopressin activity, S2:S140

Venlafaxine, S2:S1  
Ventricles, 455  
Ventricular abnormality, S2:S97  
Vigabatrin, S2:S157  
Vitamin B12, S2:S140  
Vomeronasal organ, S2:S27  
Vomeropherins, S2:S27  
Von Euler, S2:S22  
Vulnerability to medical illness, S2:S5

Vulnerability to psychiatric illness, S2:S5  
Vulnerability to substance abuse, S2:S5

## W

WAY 100135, 547  
Wingless INT-1 signalling, S2:S38  
Wistar rats, S2:S135

Word fluency, S2:S107  
Working memory, 240, 547  
World Association of Social Psychiatry, S2:S9  
World Federation of Biological Psychiatry,  
S2:S9  
World Federation of Mental Health, S2:S9  
World Health Organization, S2:S9  
World Psychiatric Association, S2:S9, S2:S10,  
S2:S58, S2:S59